We are live on ! Find out more
SGNT

SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT

Delisted

SGNT was delisted on the 29th of August, 2016.

Back to rankings

0 hedge funds and large institutions have $0 invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 128 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 128 → 0 (-128)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $486M → $0 (-$486M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 128

Holders
–
Holders Change
-128
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
128
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$97.3M
2
BFA
BlackRock Fund Advisors
California
-$36.8M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$29M
4
PCM
Penn Capital Management
Pennsylvania
-$27.7M
5
Franklin Resources
Franklin Resources
California
-$24.6M

SGNT Hedge Fund Activity: Q3 2016 in Review

0 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q3 2016, worth a combined $0 — down 100% from $486M a quarter earlier.

Sellers outnumbered buyers: 128 funds closed out of SGNT and 0 opened new positions — a net loss of 128 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vivo Capital, exiting entirely with an estimated $97.3M sold.

  • 0 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q3 2016, down from 128 in Q2 2016.
  • Funds reported $0 of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q3 2016, down 100% quarter-over-quarter.
  • 0 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q3 2016 and 128 closed out, a net change of -128 holders.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q3 2016 was Vivo Capital, an estimated $97.3M sold.

Based on aggregated 13F filings for Q3 2016.